[Development of cancer chemotherapy. Discovery of new active drugs. IV].
Lopez
M
M
Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use; D019772:Topotecan / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; C080125:9-aminocamptothecin; D000077146:Irinotecan; D019772:Topotecan; D017239:Paclitaxel; D002166:Camptothecin